Financial Shenanigans
Financial Shenanigans
Figures converted from HKD at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.
ASMPT's FY2025 accounts are clean at the audit level but stretched at the presentation level. Deloitte issued an unqualified opinion with no emphasis of matter; the only "restatement" is the mechanical reclassification of NEXX as a discontinued operation; no short-seller report, regulatory action, or class-action filing exists. Yet underneath HKFRS continuing-operations EPS of US$0.335 (more than triple the prior year) sits a single US$143.1M gain on the AAMI joint-venture disposal supplying 92% of pre-tax profit, a working-capital outflow that turned operating cash flow into a US$17.9M free cash burn, restructuring charges recurring for at least four consecutive years, and a near-doubling of trade receivables overdue more than 90 days. Nothing is hidden — management adjusts the gain out of its own non-HKFRS measures — but anchoring on HKFRS EPS will materially overstate run-rate earnings power.
1. The Forensic Verdict
Forensic Risk Score (0–100)
Yellow Flags
Red Flags
FY25 PBT from JV gain
CFO / Net Income (3y)
FCF / Net Income (3y)
Accrual Ratio (FY25)
Receivables – Revenue Growth
Verdict: Watch (35/100). Accounting is fairly stated; reported profit and reported cash flow tell different stories about FY2025 underlying performance. Grade moves to Elevated if (a) FY2026 H1 working capital absorbs more than US$64M, (b) past-due >90 day receivables continue to grow, or (c) the SMT divestiture produces a fresh "non-recurring" restructuring charge of similar magnitude. Grade returns to Clean if FY2026 CFO/NI exceeds 1.0x and restructuring drops below 1% of revenue.
No red flags, seven yellow, six green. The three valuation-relevant yellows cluster: a one-time JV gain pushing reported profit, a sharp working-capital drain, and recurring "non-recurring" charges. The cleanest tests are revenue recognition, related-party exposure, and operating-vs-financing cash-flow classification.
2. Breeding Ground
Governance is sound on paper but unusually crowded with transitions, lifting the risk that one-time items get steered into "non-recurring" buckets during a leadership reset.
The single largest breeding-ground concern is timing: a Chair handover to an 18-year-tenured INED, simultaneous CEO and CSO retirements, three additional INED departures, the AEC subsidiary liquidation, the AAMI JV disposal, the NEXX divestiture, and the SMT strategic-options review all overlap inside a 12-month window. Reporting periods where leadership and portfolio resets cluster are precisely the ones where impairment, restructuring, and one-time-gain classifications get the most management discretion.
Mitigants are credible: Big 4 auditor with no qualification, ASM International anchor with two NEDs, HKEX listing with SFC backstop. Compensation leans on revenue and operating margin, but the PSP relative-performance test caps headline-management benefit.
3. Earnings Quality
Reported HKFRS continuing earnings rose 273% YoY to US$139.4M. Roughly 91% of that increase came from a single non-operating gain.
Stripping the JV gain, AEC inventory write-off, restructuring, and impairments produces "underlying" continuing PBT of US$75.3M vs US$72.0M — 4.6% growth, not the 167% headline. Management's non-HKFRS adjusted net profit (US$60.0M FY25 vs US$48.3M FY24) tracks this underlying picture.
Receivables grew 13% on 10% revenue growth — a 3pp gap, not itself diagnostic. The deeper signal is the aging table: trade receivables overdue >90 days jumped 69%, from US$25.1M to US$42.4M; total past-due balances reached US$126.0M against gross trade receivables of US$456.4M. Management classifies these debtors as "likely to make payment" using internally developed information; FY2026 collections will test that judgment.
Finished-goods inventory rose 47% (US$114.6M to US$168.6M) while raw materials slightly declined and work-in-progress was flat. In an equipment business that recognizes revenue on customer acceptance, a finished-goods spike is consistent with year-end shipments awaiting acceptance — supported by the H2 2025 bookings ramp and book-to-bill of 1.05 — but it is also the line where stale or obsolete inventory tends to accumulate before an inventory write-off. The US$9.5M Q3 AEC write-off, triggered by the voluntary liquidation of ASMPT Equipment (Shenzhen), shows the channel is live.
The recurring-restructuring pattern is the soft red flag here. Restructuring charges have been classified as non-HKFRS adjustments in FY2023, FY2024, and FY2025; FY25 charges of US$44.1M represent 2.5% of continuing revenue and FY24 was 0.8%. Consultancy costs "incurred outside core operations" rose from US$4.7M to US$8.8M and are also adjusted out. Items that recur for three years are part of the cost base, not non-recurring; the gap between adjusted and HKFRS operating profit should be examined for materiality at every print.
4. Cash Flow Quality
The cash-flow statement is the most informative document in the FY2025 report: record reported profit, negative free cash flow.
CFO/NI fell from 2.98x in FY2024 to 0.27x in FY2025, and FCF/NI moved from 1.98x to negative. The mechanical driver is working capital.
The collapse from -US$9.5M to -US$126.9M is driven by three real items (receivables, inventory, restructuring cash-out) partially offset by two presentation items (payables stretch, customer advances). Strip the US$58.6M customer-advance build (legitimate, tied to bookings) and the US$68.5M payables stretch, and the underlying cash drag is closer to -US$245M in working capital absorption. That is the lifeline test: if FY2026 bookings and advances normalize but receivables remain elevated, CFO will compress again.
The AAMI disposal contributed US$110.7M of investing-line cash. Without it, FY2025 free cash flow (CFO minus PPE and intangible capex) was -US$32.3M against US$74.2M in FY2024. Reported dividends of US$31.0M plus the US$0.10 special dividend recommended at the AGM (~US$42M assuming 417M shares) cannot be funded from underlying operations on the FY2025 trajectory — they are funded by disposal cash and existing balance-sheet liquidity.
Disclosure is clean: AAMI cash sits in investing, the gain is separately stated above operating profit. The risk is a reader missing that the cash position grew via asset sale, not business cash generation.
Notes receivable discounted to banks with recourse fell from US$23.3M to US$2.4M, and the company correctly keeps the full carrying amount on the balance sheet with the bank cash treated as collateralized borrowing — this is the most conservative IFRS treatment for Chinese commercial-paper-style receivables discounting and is an evidence point against any "receivables-sales-disguised-as-CFO" concern. The US$38.8M derecognition of borrowings in financing activities maps cleanly to the unwind of the discounted-notes balance.
5. Metric Hygiene
Management's non-HKFRS framework is unusually candid for an HK-listed name: line-itemized in the MD&A and — uniquely for FY2025 — producing an adjusted number lower than the HKFRS print because management excludes its own one-time gain.
The HKFRS-to-adjusted gap inverted between FY2024 and FY2025. FY2024 adjusted ran higher (restructuring and Rule 3.7 takeovers expenses added back); FY2025 adjusted runs lower (AAMI gain removed). Both are internally consistent — "adjusted" is the better run-rate proxy in both directions, and the FY2025 down-move is arithmetic, not marketing.
Two definition changes to track on the next print: the NEXX reclassification will make FY2026 continuing-operations comparatives different again, and the SMT Strategic Options Assessment announced 21 January 2026 may produce a second discontinued operation. Forensic risk in the next report will rise if either generates a new "non-recurring" classification cluster.
The new associate position (Shenzhen Original Advanced Compounds, 603991.SH, 18.99% stake, US$266.7M carrying, US$303.9M quoted fair value) is 7.9% of total assets. Equity-method accounting passes through only ASMPT's share of results; mark-to-market changes do not hit P&L. The carrying-to-fair-value gap is a soft barometer of unrealized gain/loss that lives entirely outside the income statement.
6. What to Underwrite Next
Monitoring items in priority order, and the calls each would change.
Accounting risk at ASMPT is a valuation-and-position-sizing item, not a thesis breaker. Underwriters should: (1) anchor forward multiples on adjusted net profit (US$60.0M FY25 continuing), not HKFRS; (2) treat the US$110.7M AAMI proceeds as one-time, not extrapolate net-cash growth; (3) require a clean FY2026 H1 working-capital print before sizing past a tactical position; (4) discount any "non-HKFRS adjusted" restructuring add-backs that recur for a fifth consecutive year. With those adjustments, the underlying business — semi-back-end equipment with leading TCB share and 21.7% bookings growth — is what is actually being bought. The forensic risk is the gap between headline and underlying number, not the integrity of the numbers.